ENGN Logo

enGene Holdings Inc. (ENGN) Stock Forecast & Price Prediction

Live ENGN Stock Price & Analysis

Home โ€บ Stocks โ€บ Canada | NASDAQ | Healthcare | Biotechnology

$6.37

+0.07 (1.11%)

12 Month Price Forecast For ENGN

$6.37
Current Price
$322.17M
Market Cap
9 Ratings
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to ENGN Price Forecasts

+480.8%
To High Target of $37.00
+331.7%
To Median Target of $27.50
+151.2%
To Low Target of $16.00

ENGN Price Momentum

-6.0%
1 Week Change
-16.3%
1 Month Change
-19.7%
1 Year Change
-4.2%
Year-to-Date Change
-65.4%
From 52W High of $18.40
+44.1%
From 52W Low of $4.42

๐Ÿค” Considering enGene (ENGN)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 9:45 PM UTC

ENGN Analyst Ratings & Price Targets

Based on our analysis of 9 Wall Street analysts, ENGN has a bullish consensus with a median price target of $27.50 (ranging from $16.00 to $37.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $6.37, the median forecast implies a 331.7% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Colin Bristow at UBS, projecting a 480.8% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

ENGN Analyst Consensus

9
Buy
0
Hold
0
Sell

ENGN Price Target Range

Low
$16.00
Average
$27.50
High
$37.00
Current: $6.37

Latest ENGN Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for ENGN.

Date Firm Analyst Rating Change Price Target
Dec 23, 2024 HC Wainwright & Co. Andres Maldonado Buy Initiates $25.00
Dec 23, 2024 JMP Securities Silvan Tuerkcan Market Outperform Reiterates $18.00
Dec 6, 2024 JMP Securities Silvan Tuerkcan Market Outperform Reiterates $18.00
Nov 27, 2024 Raymond James Sean McCutcheon Outperform Initiates $23.00
Nov 18, 2024 JMP Securities Silvan Tuerkcan Market Outperform Initiates $18.00
Sep 24, 2024 Oppenheimer Leland Gershell Outperform Reiterates $30.00
Sep 11, 2024 Morgan Stanley Jeffrey Hung Overweight Maintains $40.00
Aug 28, 2024 Oppenheimer Leland Gershell Outperform Initiates $30.00
Apr 22, 2024 Wells Fargo Yanan Zhu Overweight Initiates $30.00
Apr 15, 2024 Guggenheim Manuel Navas Buy Initiates $34.00
Mar 28, 2024 UBS Colin Bristow Buy Initiates $37.00
Mar 8, 2024 Morgan Stanley Jeffrey Hung Overweight Initiates $40.00
Feb 20, 2024 Leerink Partners Mani Foroohar Outperform Initiates $31.00

Stocks Similar to enGene Holdings Inc.

The following stocks are similar to enGene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

enGene Holdings Inc. (ENGN) Financial Data

enGene Holdings Inc. has a market capitalization of $322.17M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -123.1%.

Valuation Metrics

Market Cap $322.17M
Enterprise Value $30.70M
P/E Ratio 0.0x
PEG Ratio -3.7x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +91.5%
Current Ratio 19.5x
Debt/Equity 10.8x
ROE -123.1%
ROA -22.1%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

enGene Holdings Inc. logo

enGene Holdings Inc. (ENGN) Company Overview

About enGene Holdings Inc.

What They Do

Develops genetic medicines for bladder cancer.

Business Model

The company operates as a clinical-stage biotechnology firm, focusing on the development of innovative genetic therapies. It generates revenue through the advancement of its lead product candidate, detalimogene voraplasmid, which targets non-muscle invasive bladder cancer patients who do not respond to existing treatments.

Additional Information

Based in Montreal, Canada, enGene Holdings Inc. aims to address significant unmet medical needs in bladder cancer treatment. Its unique non-viral monotherapy approach positions it within a niche market with potential for high impact and growth.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

31

CEO

Mr. Jason D. Hanson Esq., J.D.

Country

Canada

IPO Year

2023

enGene Holdings Inc. (ENGN) Latest News & Analysis

ENGN stock latest news image
Quick Summary

enGene Holdings Inc. announced that its lead investigational product, detalimogene voraplasmid, is in a pivotal study for treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Why It Matters

The announcement highlights enGene's pivotal study progress on a novel cancer treatment, which could significantly impact its market value and investor sentiment if successful.

Source: Business Wire
Market Sentiment: Neutral
ENGN stock latest news image
Quick Summary

enGene Holdings Inc. announced inducement equity awards as it continues a pivotal study on its investigational product, detalimogene voraplasmid, for treating high-risk bladder cancer.

Why It Matters

enGene's pivotal study on a novel treatment for a severe cancer type could impact its stock value and attract investor interest, indicating potential for future growth or partnerships.

Source: Business Wire
Market Sentiment: Neutral
ENGN stock latest news image
Quick Summary

enGene Holdings Inc. (Nasdaq: ENGN) announced three poster presentations related to their investigational product, detalimogene voraplasmid, at an upcoming conference. The product is in a pivotal study for high-risk bladder cancer.

Why It Matters

enGene's ongoing pivotal study and poster presentations highlight progress in treating a significant cancer type, potentially impacting its valuation and attracting investor interest in genetic therapies.

Source: Business Wire
Market Sentiment: Neutral
ENGN stock latest news image
Quick Summary

Wall Street analysts set a price target for enGene Holdings Inc. (ENGN) suggesting a potential upside of 238.8%, supported by positive earnings estimate revisions.

Why It Matters

A 238.8% upside in price targets suggests significant growth potential for enGene Holdings Inc. (ENGN), bolstered by positive earnings revisions, attracting investor interest.

Source: Zacks Investment Research
Market Sentiment: Positive
ENGN stock latest news image
Quick Summary

enGene Holdings Inc. reported its financial results for the year, while its lead product, detalimogene voraplasmid, is in a pivotal study for high-risk BCG-unresponsive bladder cancer.

Why It Matters

enGene's financial results and ongoing pivotal study highlight its potential to innovate in cancer treatment, impacting stock performance and investor sentiment in biotech.

Source: Business Wire
Market Sentiment: Neutral
ENGN stock latest news image
Quick Summary

enGene Holdings Inc. (ENGN) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating positive sentiment regarding its earnings prospects.

Why It Matters

Growing optimism and a Zacks Rank #1 indicates strong earnings potential, suggesting potential price appreciation for enGene Holdings Inc. (ENGN) shares.

Source: Zacks Investment Research
Market Sentiment: Positive

Frequently Asked Questions About ENGN Stock

What is enGene Holdings Inc.'s (ENGN) stock forecast for 2025?

Based on our analysis of 9 Wall Street analysts, enGene Holdings Inc. (ENGN) has a median price target of $27.50. The highest price target is $37.00 and the lowest is $16.00.

Is ENGN stock a good investment in 2025?

According to current analyst ratings, ENGN has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.37. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for ENGN stock?

Wall Street analysts predict ENGN stock could reach $27.50 in the next 12 months. This represents a 331.7% increase from the current price of $6.37. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is enGene Holdings Inc.'s business model?

The company operates as a clinical-stage biotechnology firm, focusing on the development of innovative genetic therapies. It generates revenue through the advancement of its lead product candidate, detalimogene voraplasmid, which targets non-muscle invasive bladder cancer patients who do not respond to existing treatments.

What is the highest forecasted price for ENGN enGene Holdings Inc.?

The highest price target for ENGN is $37.00 from Colin Bristow at UBS, which represents a 480.8% increase from the current price of $6.37.

What is the lowest forecasted price for ENGN enGene Holdings Inc.?

The lowest price target for ENGN is $16.00 from at , which represents a 151.2% increase from the current price of $6.37.

What is the overall ENGN consensus from analysts for enGene Holdings Inc.?

The overall analyst consensus for ENGN is bullish. Out of 9 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $27.50.

How accurate are ENGN stock price projections?

Stock price projections, including those for enGene Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.